Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer - A Proof of Concept, Open Label Non-randomized Phase IIa Study. The AVETUXIRI Trial

NCT03608046 is registered in ClinicalTrials.gov with Cliniques universitaires Saint-Luc- Université Catholique de Louvain as lead sponsor.

NCT NCT03608046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03608046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer - A Proof of Concept, Open Label Non-randomized Phase IIa Study. The AVETUXIRI Trial
Lead sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase
Phase 2
Overall status
Unknown status
Start date
October 3, 2018
Completion date
December 31, 2023
Enrollment
59 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms, malignant